Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study

医学 安慰剂 耐受性 临床终点 内科学 脾切除术 不利影响 意向治疗分析 胃肠病学 中性粒细胞减少症 临床试验 外科 化疗 脾脏 病理 替代医学
作者
Xiaofan Liu,Hu Zhou,Yu Hu,Jie Yin,Junmin Li,Wen-Ming Chen,Ruibin Huang,Yuping Gong,Chengwei Luo,Heng Mei,Bingjie Ding,Chengyuan Gu,Huiping Sun,Yun Leng,Dexiang Ji,Yan Li,Hongyan Yin,Haiyan Shi,Keyan Chen,Jian Wang
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:10 (6): e406-e418 被引量:26
标识
DOI:10.1016/s2352-3026(23)00034-0
摘要

Spleen tyrosine kinase (Syk) inhibitor is a treatment option for primary immune thrombocytopenia. We aimed to evaluate the safety, tolerability, pharmacokinetics, preliminary activity, and recommended phase 2 dose of sovleplenib in patients with primary immune thrombocytopenia.This randomised, double-blind, placebo-controlled, phase 1b/2 study was conducted at nine hospitals in China. Eligible patients were aged 18-75 years, had an ECOG performance score of 0-1, had primary immune thrombocytopenia for more than 6 months, and did not respond or relapsed after previous first-line treatment or had poor response or postoperative relapse after a splenectomy. Dose-escalation (100 mg, 200 mg, or 300 mg given orally once a day) and dose-expansion phases (recommended phase 2 dose) each consisted of an 8-week, double-blind, placebo-controlled period in which patients were randomly assigned (3:1) to receive sovleplenib or placebo with an interactive web response system followed by a 16-week, open-label period with sovleplenib. Patients, investigators, and the sponsor were masked to treatment allocation during the first 8 weeks. The main efficacy endpoint was the proportion of patients whose platelet count reached 30 × 109 platelets per L or higher and was double of the baseline at two consecutive visits during 0-8 weeks without rescue therapy. Efficacy was evaluated by intention-to-treat. This study is registered with ClinicalTrials.gov, NCT03951623.Between May 30, 2019, and April 22, 2021, 62 patients were assessed for eligibility and 45 (73%) were randomly assigned. Patients received at least one dose of the study drug during the 8-week double-blind period (placebo [n=11] and sovleplenib 100 mg [n=6], 200 mg [n=6], 300 mg [n=16], and 400 mg [n=6]; this group was added following the observation of no protocol-specified safety events at the previous doses). All participants were Asian; 18 (40%) of 45 were male and 27 (60%) were female. The median age was 40·0 years (IQR 33·0-50·0). Ten (29%) of 34 patients in sovleplenib groups versus five (45%) of 11 in the placebo group received concomitant anti-primary immune thrombocytopenia therapy. The recommended phase 2 dose was determined as 300 mg once a day. The proportion of patients who met the main efficacy endpoint were three (50%; 95% CI 12-88) in the 100 mg group, three (50%; 12-88) in the 200 mg group, ten (63%; 35-85) in the 300 mg group, and two (33%; 4-78) in the 400 mg group compared with one (9%; 0-41) in the placebo group. The overall response rate in the 300 mg group was 80% (16 of 20 who received continuous sovleplenib plus those who crossed over from placebo) and the durable response rate was 31% (11-59; five of 16) in the continuous sovleplenib 300 mg and 75% (19-99; three of four) crossed from placebo to sovleplenib during 0-24 weeks. During the 28-day safety evaluation period, two grade 2 or worse treatment-related treatment-emergent adverse events occurred in the sovleplenib groups (hypertriglyceridaemia and anaemia). During 0-8 weeks, the most frequent treatment-emergent adverse events were an increase in blood lactate dehydrogenase, haematuria, and urinary tract infection (seven [21%] of 34 in sovleplenib groups vs one [9%] of 11 in the placebo group); and occult blood-positive and hyperuricaemia (four [12%] vs three [27%] for each). No fatal treatment-emergent adverse events were recorded.Sovleplenib was well tolerated, and the recommended phase 2 dose showed a promising durable response in patients with primary immune thrombocytopenia, which provides evidence for future investigations. A phase 3 trial is ongoing (NCT05029635) to confirm the efficacy and safety of sovleplenib in patients with primary immune thrombocytopenia.HUTCHMED.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zorro3574完成签到,获得积分10
1秒前
1秒前
踏实的盼柳的应助被WaNgBO采纳,获得10
1秒前
1秒前
2秒前
BANANA发布了新的文献求助10
2秒前
王乐安完成签到,获得积分10
2秒前
Able完成签到 ,获得积分10
3秒前
时尚篮球完成签到,获得积分10
3秒前
3秒前
赘婿的应助被we采纳,获得10
5秒前
行者发布了新的文献求助10
5秒前
kkm发布了新的文献求助10
6秒前
6秒前
韶枫完成签到,获得积分10
6秒前
滴滴答答发布了新的文献求助10
6秒前
kakak完成签到,获得积分10
7秒前
哈哈哈完成签到 ,获得积分10
7秒前
落幕无悔完成签到 ,获得积分10
7秒前
蜜雪冰城完成签到,获得积分10
8秒前
乌黑的眼圈完成签到,获得积分10
8秒前
8秒前
xtc发布了新的文献求助10
9秒前
10秒前
10秒前
YanChengHan完成签到,获得积分10
11秒前
在水一方的应助被陆羽泡的茶采纳,获得10
11秒前
致恒夏发布了新的文献求助10
11秒前
lc发布了新的文献求助10
12秒前
Aj发布了新的文献求助10
13秒前
风吹麦浪的应助被刘乐会采纳,获得10
13秒前
乐观地sail发布了新的文献求助10
13秒前
14秒前
传奇3的应助被11111采纳,获得10
14秒前
李若菲完成签到,获得积分10
15秒前
今后的应助被ZZShuang采纳,获得10
15秒前
李健的应助被吃肯德基采纳,获得10
15秒前
Owen的应助被4u采纳,获得10
16秒前
共享精神的应助被行者采纳,获得50
17秒前
xtc完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158017
求助须知:如何正确求助?哪些是违规求助? 9553900
关于积分的说明 21716555
捐赠科研通 7747340
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551639
邀请新用户注册赠送积分活动 2471005